|Bid||42.3500 x 900|
|Ask||42.3900 x 800|
|Day's Range||42.1100 - 42.4060|
|52 Week Range||36.5000 - 44.5400|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.28%|
The company will be launching its Phase 3 TAHOE study to compare Rova-T with topotecan, the only therapy in second line SCLC approved by the FDA (U.S. Food & Drug Administration). AbbVie also aims to establish the importance of targeting tumor-initiating cells in treating solid tumors. Beyond 2020, the company plans to launch the MERU study, which will enable Rova-T to expand its label in the first line SCLC maintenance indication.
While a rise in interest rates would diminish the attractiveness of dividend stocks, investors are chasing these on optimism surrounding the biggest tax overhaul in decades.